

p53 directly transactivates $\Delta 133p53\alpha$, regulating cell fate outcome in response to DNA damage

M Aoubala^{1,3}, F Murray-Zmijewski^{1,3}, MP Khoury^{1,2}, K Fernandes¹, S Perrier¹, H Bernard^{1,2}, A-C Prats², DP Lane¹ and J-C Bourdon^{*1,2}

We have previously reported that the human *p53* gene encodes at least nine different *p53* isoforms, including $\Delta 133p53\alpha$, which can modulate *p53* transcriptional activity and apoptosis. In this study, we aimed to investigate the regulation of $\Delta 133p53\alpha$ isoform expression and its physiological role in modulating cell cycle arrest and apoptosis. We report here that in response to a low dose of doxorubicin (which induces cell cycle arrest without promoting apoptosis), *p53* directly transactivates the human *p53* internal promoter, inducing $\Delta 133p53\alpha$ protein expression. The induced $\Delta 133p53\alpha$ then inhibits *p53*-dependent apoptosis and G1 arrest without inhibiting *p53*-dependent G2 arrest. Therefore, endogenous $\Delta 133p53\alpha$ does not exclusively function in a dominant-negative manner toward *p53*, but differentially regulates cell cycle arrest and apoptosis.

Cell Death and Differentiation (2011) 18, 248–258; doi:10.1038/cdd.2010.91; published online 6 August 2010

The *p53* tumor suppressor protein is a transcription factor that prevents damaged cells to proliferate in response to various cellular stresses.^{1–3} However, the ways by which *p53* determines the cell fate outcome remain elusive.⁴ So far, the best described mechanism is its ability to modulate gene expression by binding directly and specifically to *p53* responsive elements (*p53*REs) on DNA.⁵

We previously established that the human *p53* gene expresses nine *p53* protein isoforms (*p53*, *p53 β* , *p53 γ* , $\Delta 40p53\alpha$, $\Delta 40p53\beta$, $\Delta 40p53\gamma$, $\Delta 133p53\alpha$, $\Delta 133p53\beta$ and $\Delta 133p53\gamma$) because of alternative splicing, alternative initiation of translation at codon 40 and alternative internal promoter. The $\Delta 133p53\alpha$, $\Delta 133p53\beta$ and $\Delta 133p53\gamma$ isoforms are N-terminally truncated *p53* protein isoform deleted of the first 132 aa, of which mRNA is initiated from the internal promoter in intron-4 of the human *p53* gene.^{6,7} *p53* isoforms are expressed in normal human tissues and in tumors.^{8–15}

We have previously shown that ectopically expressed $\Delta 133p53\alpha$ negatively regulates *p53* tumor suppressor activity by inhibiting *p53*-mediated apoptosis.⁶ However, little is known about the molecular mechanisms by which human $\Delta 133p53\alpha$ modulates *p53* activities at physiological level.

In this study, we investigated the regulation of $\Delta 133p53\alpha$ expression and its physiological role in modulating the cellular response to DNA damage. We determined that endogenous $\Delta 133p53\alpha$ does not exclusively function in a dominant-negative manner toward *p53* to regulate gene expression.

Results

Mapping of the *p53* internal promoter within intron-4 of the human *p53* gene.

In the *p53* homologous genes, *p63* and *p73*, ΔN isoforms are transcribed from an internal promoter (P2), located within intron-3 of both genes.¹⁵ We previously established that human *p53* gene contains an internal promoter located in the intron-4.⁶ To map the transcription initiation site of *p53* internal promoter (1555 bp upstream of exon-5 of the human *p53* gene), we generated different luciferase reporter constructs (Figure 1A), which were transfected into *p53*-null H1299 cells. As shown in Figure 1B, the 1555 bp fragment (*pi3i4luc a*) contains a promoter activity. Its activity is similar to the basal promoter activity of *Bax* and is approximately four times greater than the basal activity of the promoterless *pGL3-basic* plasmid. Deletion of residues 1–1304 (Figure 1A, constructs c, d and f) did not abolish the promoter activity (Figure 1B, c, d and f), suggesting that the minimum *p53* internal promoter region is located within the last 251 bp of the intron-4 (Figure 1A, f).

Moreover, the minimum *p53* internal promoter (Figure 1B, f) showed a significant increase in the basal promoter activity (fourfold), as compared with the basal activity of the *pi3i4-luc* construct (Figure 1B, a), suggesting that the region 1–1304 bp contains negative regulatory elements such as silencers. In fact, the basal promoter activity of the construct f (1304–1555) is increased by threefold compared with the basal promoter activity of the construct d (1042–1555), suggesting that the region 1042–1304 contains a silencer element. Deletion of

¹Centre for Oncology and Molecular Medicine, Inserm-European Associated Laboratory U858, University of Dundee, College of Medicine, Dundee, DD1 9SY, UK and

²Institut de Médecine Moléculaire de Rangueil, Unité mixte Inserm U858, IFR 150, 1, Avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France

*Corresponding author: J-C Bourdon, Centre for Oncology and Molecular Medicine, Inserm-European Associated Laboratory U858, University of Dundee, College of Medicine, Dundee DD1 9SY, UK. Tel: +44 (0)13 82 496 400; Fax: +44 (0)13 82 496 363; E-mail: j.bourdon@dundee.ac.uk

³These authors contributed equally to this work.

Keywords: *p53* isoforms; splice; cancer; DNA damage; apoptosis; cell cycle

Abbreviations: *p53*RE, *p53* responsive element; siRNA, small interfering RNA; siNS, non-specific siRNA; si133a, siRNA specific for $\Delta 133p53$ mRNAs; si133b, siRNA specific for $\Delta 133p53$ mRNAs; siTA, siRNA targeting specifically exon-2 of *p53* mRNAs

Received 10.7.09; revised 21.5.10; accepted 24.5.10; Edited by M Oren; published online 06.8.10




Figure 1 Mapping of the promoter activity within intron-4 of the *p53* gene. **(A)** Diagram showing the different *p53* internal promoter deletion constructs (a–f), generated as described in Materials and Methods. Positions of the different restriction enzymes and size of the fragments obtained are indicated. Numbers of *p53* introns and exons (empty and shadow boxes, respectively) are indicated. **(B)** Basal activity of each *p53* internal promoter deletion construct (a–f). H1299 cells were co-transfected with each of the *p53* internal promoter deletion constructs (a–f) and the Renilla luciferase reporter plasmid. The dual luciferase assay was then performed, as described in Materials and Methods. Each experiment was performed in duplicate and all results shown are the average of at least three separate individual experiments. The promoterless pGL3-basic plasmid was used as a negative control and pBax-luc plasmid was used as a positive control for the luciferase promoter activity. All activities were normalized to pGL3-basic activity

the last 251 bp from the 3' end of intron-4 (Figure 1A, constructs b and e) completely abolishes the promoter activity (Figure 1B, b and e), confirming that the initiation site of the *p53* internal promoter is located within the last 250 bp of intron-4 of the human *p53* gene.

Human $\Delta 133p53$ is a direct p53 target gene. Using our bioinformatic software and our refined consensus p53RE,¹⁶ we identified a cluster of five p53 consensus decamers at the junction of exon-4 and intron-4 of the human *p53* gene corresponding to the residues 757–804 in the pi3i4-luc construct (Figure 2A, dashed box).

To determine whether p53 directly transactivates its own internal promoter, deletion constructs c and d (Figure 1A) were assessed for their responsiveness to p53 (Figure 2A, c and d, respectively). A luciferase construct driven by the *p21* promoter was used as a positive control. As shown in Figure 2B, p53 induced the luciferase activity in all constructs containing the putative p53RE (Figure 2A, a and c). Interestingly, the greatest induction (sixfold) was obtained with the construct containing the 723–1555 bp fragment (Figure 2A, construct c), which contains all five decamers, but lacks the upstream 722 bp region of the *p53* internal promoter. This suggests that the region (1–722) contains

several negative regulatory elements. Interestingly, deletion of the five putative decamers (Figure 2A, construct d) resulted in a significant decrease in p53 responsiveness (Figure 2B, d compared with c) without abolishing it, suggesting that p53 can induce *p53* internal promoter through other transcription factors. Bioinformatics analysis revealed that the *p53* internal promoter could be regulated by other transcription factors, including AP1, elk-1, N-myc, E2F, HIF-1 α , HSF1 and ER (Supplementary Figure A).

To further confirm that the p53RE is functional, four single base mutations were generated by site-directed mutagenesis within the first two decamers of the internal promoter. As shown in Figure 2C, the four mutations are sufficient to significantly decrease p53 transactivation of the entire *p53* internal promoter (construct a). This result clearly demonstrates that intron-4 of the *p53* gene contains a functional p53RE. However, these mutations do not completely abolish p53 activation probably because of the presence of the remaining decamers. Further analysis will be required to establish whether the remaining decamers can confer responsiveness to p53.

Endogenous p53 can directly bind to and transactivate its internal promoter. We next investigated whether




Figure 2 Identification and characterization of five p53REs within the p53 internal promoter. (A) Diagram showing the identified p53REs (written in bold and in capital letters within the region of 757–804 bp). Constructs with (a, c) or without (d) the p53REs were generated, as described in Materials and Methods. p53 introns and exons (empty and shadow boxes, respectively) are indicated. 4i corresponds to intron-4. p53RE region is indicated with a dashed box. (B) Induction of the p53 internal promoter by p53. H1299 cells were co-transfected with each of the p53 internal promoter constructs (a, c and d) and the p53 expression vector or the empty expression vector pSI. The dual luciferase assay was then performed, each experiment was performed in duplicate and all results shown are the average of at least three separate individual experiments. The p53-inducible p21 promoter cloned upstream of the luciferase gene was used as a positive control (p21). All luciferase activities were normalized to the basal activity obtained with the empty pSI plasmid and are represented as fold activation. (C) Four single point mutations (underlined) were generated within the first two p53REs of the pi3i4-luc construct (A, a). WT p53RE and Mutant p53RE sequences are illustrated. H1299 were co-transfected with the pi3i4-luc construct (WT p53RE or Mutant p53RE) and the p53 expression vector or the empty expression vector PSI. The dual luciferase assay was then performed, each experiment was performed in duplicate and all results shown are the average of at least three separate individual experiments. All luciferase activities were normalized to the basal activity of the empty pSI plasmid and are represented as fold activation

endogenous p53 could directly bind to and transactivate its own internal promoter. MCF7 cells (WTP53) were left untreated or treated with 60 ng/ml of actinomycin D (Act D)

for 2 h and a chromatin immunoprecipitation (ChIP) assay was performed. The immunoprecipitated DNA was quantified by RT-qPCR (Figure 3a). A probe and primers specific for a




Figure 3 Human p53 internal promoter is directly transactivated by p53. (a) ChIP assay of p53 internal promoter DNA was carried out by RT-qPCR in MCF7 cells that were left untreated or treated with 60 ng/ml of actinomycin D (Act D) and harvested 2 h after treatment, using primers encompassing the p53REs. Exon-8 amplification was performed as a negative control. The amounts of the p53 internal promoter contained in the input or immunoprecipitated with the DO-1 antibody were quantified by RT-qPCR, as previously described.²⁹ The results are expressed as a percentage of promoter specifically immunoprecipitated by the DO-1 antibody, compared with the total amount of promoter contained in 10% of the input. The results shown are the average of three independent experiments. (b–e) Quantification of endogenous p53 internal promoter activity by RT-qPCR in human cancer cells (MCF7, MCF7-DDp53, HCT116^{-/-}, HCT116^{+/+} and U2OS) or primary normal human dermal fibroblasts (NHDF). (b) MCF7 (WTp53) and MCF7-DDp53 (mutant p53) cells were left untreated or treated for 30 min, 1 h or 2 h with 60 ng/ml of Act D and harvested. (c) HCT116^{+/+} (WTp53) and HCT116^{-/-} (devoid of FLp53 expression) cells were left untreated or treated for 1 h with 0.5 μ M of doxorubicin (Doxo) and harvested at the indicated time (d) U2OS (WTp53) cells and (e) NHDF were left untreated or treated for 1 h with 0.5 μ M of doxorubicin (Doxo) and harvested 24 h after treatment. Student's *t*-test was performed and *P*-values are indicated (the student's *t*-tests were determined by comparing the expression levels of the p53 internal promoter in cells treated with Act D or doxorubicin, to untreated cells). ***P* < 0.01; ****P* < 0.001. For all RT-qPCR experiments, expression levels were normalized to TBP. Results are expressed as the fold change compared with untreated cells and represent mean \pm S.D. of three independent experiments

region within the *GAPDH* gene that is not bound by p53, was used as a negative control. The binding of p53 to the p21 promoter was analyzed as a positive control (Supplementary Figure B1). We further quantified the genomic DNA co-immunoprecipitated with p53 protein and containing either the p53RE (intron-4) or exon-8 of the p53 gene. In unstressed cells (Figure 3a), no significant binding of p53 to either intron-4 or exon-8 was observed. However, following

Act D treatment, endogenous p53 was bound to intron-4, but not to exon-8, demonstrating that p53 binds to its own internal promoter.

RT-qPCR experiments were carried out in MCF7 and MCF7-DDp53 (devoid of functional p53) cells, to determine whether there is a p53-dependent induction of $\Delta 133p53$ mRNAs in response to Act D. (Figure 3b). We designed a probe and primers from the unique 5'UTR region of $\Delta 133p53$

mRNAs, encoding $\Delta 133p53\alpha$, $\Delta 133p53\beta$ and $\Delta 133p53\gamma$, to quantify the transcriptional activity of the *p53* internal promoter. p21 mRNA expression was determined as a positive control (Supplementary Figure B2). In Figure 3b, the expression of $\Delta 133p53$ mRNAs is significantly induced 2 h following Act D treatment in MCF-7 cells, but no induction of $\Delta 133p53$ mRNAs was seen in MCF7-DDp53 cells, confirming that the induction of $\Delta 133p53$ mRNAs is p53-dependent.

To assess $\Delta 133p53$ mRNAs induction in other cell lines, we compared the expression of $\Delta 133p53$ mRNAs in response to doxorubicin treatment in colorectal carcinoma cell lines, expressing WTP53 (HCT116 +/+) or devoid of full-length p53 (FLp53) expression (HCT116 -/-). In HCT116 -/- cells, the *neomycin* gene has been integrated within exon-2 of the *p53* gene, resulting in the loss of FLp53 expression.¹⁷ However, HCT116 -/- cells still express p53 isoforms at the mRNA and protein levels ($\Delta 40p53$ and $\Delta 133p53$ isoforms).^{7,18} We show here that $\Delta 133p53$ mRNAs are inducible in response to doxorubicin only in HCT116 +/+, but not in HCT116 -/- cells (Figure 3c). Similar results were obtained in response to etoposide treatment (data not shown). We further determined that $\Delta 133p53$ mRNAs is significantly induced on doxorubicin treatment in U2OS osteosarcoma cell line (WTP53) and primary normal human dermal fibroblasts (NHDF; Figure 3d and e, respectively). Altogether, these results demonstrate that *in vivo*, the *p53* internal promoter located within intron-4, is directly transactivated by p53 in response to DNA damage in multiple cell lines.

$\Delta 133p53\alpha$ protein expression is induced by p53 in response to DNA damage. Western blot analyses were performed to determine whether the increase of $\Delta 133p53\alpha$ protein is associated with the expression of $\Delta 133p53$ mRNAs. The rabbit polyclonal antibody CM1 can detect all p53 protein isoforms, including $\Delta 133p53\alpha$. We thus analyzed $\Delta 133p53\alpha$ protein expression in HCT116 +/+ and HCT116 -/- cells, treated or not with doxorubicin. To prevent any *in vitro* protein degradation, cells were directly lysed in SDS-Laemmli buffer. Upon doxorubicin treatment, HCT116 +/+ cells induces p53 and some p53 isoforms migrating at 48, 45 and 35 kDa (Figure 4a). In HCT116 -/-

cells, a strong expression of $\Delta 40p53$ was detected, but neither $\Delta 40p53$ nor other p53 isoforms were induced in response to doxorubicin treatment. To identify the bands corresponding to $\Delta 133p53\alpha$, we designed two distinct small interfering RNAs (siRNAs; si133a and si133b), which specifically target the 5'UTR of $\Delta 133p53$ mRNA variants.

Having confirmed the specificity and efficiency of si133a or si133b (Supplementary Figure C1), we transfected HCT116 cells with si133a, si133b or non-specific siRNA (siNS) as a negative control (Figure 4b). Doxorubicin treatment induced the expression of p53 and also of some p53 isoforms migrating at 48, 45 and 35 kDa (Figure 4b lane 5 compared with 1). The two $\Delta 133p53$ siRNAs, si133a and si133b, did not alter the level of endogenous p53 or of the other p53 isoforms (corresponding to the bands at 48 and 45 kDa), but specifically reduced the expression of the 35 kDa band (Figure 4b, lanes 4, 6 compared with 5), indicating that the 35 kDa band corresponds to endogenous $\Delta 133p53\alpha$ protein.

The induction of $\Delta 133p53\alpha$ protein was further confirmed by western blot analysis in primary NHDF treated with doxorubicin (Figure 4c). Altogether, these results demonstrate that in the cancer derived cell lines (HCT116 WTP53) and in the normal primary fibroblasts, $\Delta 133p53\alpha$ isoform is induced by p53 at both mRNA and protein levels in response to DNA damage.

Generation and characterization of U2OS-ctrl and U2OS- $\Delta 133p53$ cells. To determine the role of $\Delta 133p53\alpha$ in the cellular response to DNA damage, we investigated using bromodeoxyuridine (BrdU) cell cycle analysis and apoptosis assay (annexinV assay), the experimental conditions that trigger cell cycle arrest, but not apoptosis of U2OS cells in response to doxorubicin. We established that U2OS cells grown for 24 h at 50% confluence and treated with a low dose of doxorubicin (0.5 μ M for 1 h), trigger G2 cell cycle arrest without promoting apoptosis 24 h after treatment. Those experimental conditions were then used in all the following experiments.

Two cellular models were generated to define the biological relevance of $\Delta 133p53\alpha$ induction in response to DNA damage. U2OS cells were stably transfected with the empty




Figure 4 $\Delta 133p53\alpha$ protein is induced in response to doxorubicin treatment. (a) HCT116 +/+ (p53WT) and HCT116 -/- (devoid of FLp53 expression) cells were treated with 0.5 μ M doxorubicin for 1 h and proteins were extracted 24 h after treatment in SDS-Laemmli buffer. Western blot analysis was performed using the CM1 rabbit polyclonal antibody, which recognizes all p53 isoforms. (b) HCT116 +/+ transfected for 24 h with 50 nM of si133a, si133b (two distinct siRNAs specific for the 5'UTR of $\Delta 133p53$ mRNAs) or siNS (nonspecific siRNA used as a negative control), were left untreated (-) or treated (+) for 1 h with 0.5 μ M of doxorubicin, as indicated. Proteins were extracted 24 h after treatment and analyzed by western blotting. p53 and its isoforms were revealed with the CM1 antibody. Actin was used as a protein loading control. (c) Western blot analysis of endogenous $\Delta 133p53\alpha$ expression in untreated (-) or doxorubicin-treated (+) NHDF cells. p53 and its isoforms were revealed with the CM1 antibody. Tubulin was used as a protein loading control

pcDNA3 or pcDNA3- $\Delta 133p53\alpha$ expression vectors, to generate U2OS-ctrl and U2OS- $\Delta 133p53$ cells, respectively.

First, we analyzed ectopic $\Delta 133p53\alpha$ protein expression in U2OS- $\Delta 133p53$ cells by western blot analysis, using the CM1 antibody (Figure 5A). U2OS- $\Delta 133p53$ cells transfected with si133a, si133b or siNS were left untreated or treated with doxorubicin (0.5 μ M, 1 h). As shown in Figure 5A, lane 1, ectopic $\Delta 133p53\alpha$ protein was expressed at 35 kDa. A weaker band at 32 kDa could also be detected and may correspond to a post-translationally modified form of $\Delta 133p53\alpha$. Transfection of U2OS- $\Delta 133p53$ cells with si133a or si133b specifically knock down the bands at 35 and 32 kDa corresponding to ectopic $\Delta 133p53\alpha$ protein, without affecting p53 protein level (Figure 5A, lanes 2, 3 compared with 1). In U2OS- $\Delta 133p53$ cells, doxorubicin treatment induced p53 protein expression, but had no detectable effect on $\Delta 133p53\alpha$ protein level (Figure 5A, lane 4 compared with 1). This is because the ectopic expression of $\Delta 133p53\alpha$, driven by the CMV promoter (pcDNA3 plasmid), is exceeding the endogenous expression level and therefore masks the induction of endogenous $\Delta 133p53\alpha$ (Figure 5B lane 1 compared with 7). Depletion of $\Delta 133p53\alpha$ by si133a or si133b was equally efficient in doxorubicin-treated and untreated U2OS- $\Delta 133p53$ cells (Figure 5A, lanes 2, 3 compared with 1 and lanes 5, 6 compared with 4). The induction of p53 in response to doxorubicin is comparable in U2OS- $\Delta 133p53$ cells transfected with si133a, si133b or siNS (Figure 5A, lanes 5, 6 compared with 4). Therefore, p53 can be induced in U2OS- $\Delta 133p53$ cells in response to doxorubicin treatment.

To compare the expression level of $\Delta 133p53\alpha$ protein in U2OS-ctrl and U2OS- $\Delta 133p53$ cells, the same amount of protein from U2OS- $\Delta 133p53$ cells was loaded in Figure 5A, lane 1 and in Figure 5B, lane 1. Endogenous $\Delta 133p53\alpha$ protein was not detectable in untreated U2OS-ctrl cells (Figure 5B, lanes 2 and 3). Transfection of si133a or si133b did not affect the expression of p53 in untreated U2OS-ctrl cells (Figure 5B, lanes 4 and 5). In response to doxorubicin (0.5 μ M, 1 h), endogenous $\Delta 133p53\alpha$ was induced in U2OS-ctrl cells (Figure 5B, lane 3 compared with 7). It is noteworthy that in U2OS-ctrl cells treated with doxorubicin, endogenous $\Delta 133p53\alpha$ protein is induced, but is far less expressed than ectopic $\Delta 133p53\alpha$ protein in U2OS- $\Delta 133p53$ cells (Figure 5B lane 7 compared with 1). Transfection of U2OS-ctrl cells with si133a or si133b inhibited the induction of endogenous $\Delta 133p53\alpha$ protein in response to doxorubicin (Figure 5B, lanes 8, 9 compared with 7). To determine whether the induction of $\Delta 133p53\alpha$ in doxorubicin-treated U2OS-ctrl cells is p53-dependent, cells were transfected with siTA, an siRNA that specifically targets p53 mRNAs containing exon-2 of the *p53* gene without targeting $\Delta 133p53$ mRNAs. The results show that $\Delta 133p53\alpha$ protein induction is inhibited in doxorubicin-treated U2OS-ctrl cells depleted of p53 expression, confirming that $\Delta 133p53\alpha$ is induced by p53 (Figure 5B, lane 6 compared with 7).

Human $\Delta 133p53\alpha$ antagonizes p53-mediated apoptosis and G1 cell cycle arrest without preventing G2 cell cycle arrest. We next investigated whether the cellular response to DNA damage could be regulated by modulating $\Delta 133p53\alpha$ expression. U2OS-ctrl and U2OS- $\Delta 133p53$ cells were

transfected with si133a, si133b or siNS and were left untreated or treated with doxorubicin (0.5 μ M, 1 h) for 24 h. In parallel to the western blots presented in Figure 5A and B, cell cycle progression (Figure 5C–E) and apoptosis (Figure 5F) were also analyzed using BrdU assay and Annexin-V assay, respectively. A representative BrdU experiment is shown in Figure 5C. Untreated U2OS-ctrl and U2OS- $\Delta 133p53$ cells transfected with siNS showed similar cell cycle progression and a low percentage of spontaneous apoptosis (8%), indicating that overexpression of $\Delta 133p53\alpha$ does not alter cell cycle progression and apoptosis in untreated cells (Figure 5C-a, C-b, D, E and F).

U2OS-ctrl and U2OS- $\Delta 133p53$ cells transfected with siNS and treated with a low dose of doxorubicin show statistically similar cell cycle progression with about 3% of cells arrested in G1 and 79% of cells arrested in G2 (Figure 5C-c, C-d and E). In both cell lines, the low dose of doxorubicin did not significantly increase apoptosis compared with untreated cells (Figure 5F). Altogether, this indicates that overexpression of $\Delta 133p53\alpha$ in U2OS- $\Delta 133p53$ cells does not alter the cellular response to a low dose of doxorubicin, compared with U2OS-ctrl cells (Figure 5C-c, C-d, D, E and F). U2OS-ctrl cells were transfected with siTA, we detected a statistically significant decrease in the percentage of cells arrested in G2 (Figure 5E) and in the percentage of apoptotic cells, compared with doxorubicin-treated U2OS-ctrl cells transfected with siNS (Figure 5F). This is consistent with previous publications reporting that doxorubicin induces G2 cell cycle arrest and apoptosis in a p53-dependent manner in U2OS cells.¹⁹ As we have previously reported that overexpression of $\Delta 133p53\alpha$ can function in a dominant negative manner toward p53,^{6,7} it is surprising that the overexpression of $\Delta 133p53\alpha$ in U2OS- $\Delta 133p53$ cells does not inhibit p53-mediated G2 arrest. It implies that $\Delta 133p53\alpha$ does not exclusively function in a dominant-negative manner toward p53.

Strikingly, in response to doxorubicin treatment, depletion of the $\Delta 133p53$ isoforms with si133a or si133b significantly enhanced the percentage of U2OS-ctrl cells in G1 arrest (16 and 26%, respectively, Figure 5C-e and D), suggesting that endogenous $\Delta 133p53\alpha$ inhibits G1 cell cycle arrest in U2OS-ctrl cells. To confirm this, U2OS cells overexpressing $\Delta 133p53\alpha$ (U2OS- $\Delta 133p53$) were transfected with si133a or si133b. Although both siRNAs inhibit $\Delta 133p53\alpha$ expression in U2OS- $\Delta 133p53$ cells, $\Delta 133p53\alpha$ protein level was still overexpressed compared with endogenous $\Delta 133p53\alpha$ protein level in U2OS-ctrl cells (Figure 5A). Transfection of si133a or si133b in U2OS- $\Delta 133p53$ does not significantly change the percentage of cells in G1 in response to treatment (Figure 5C-f and D), confirming that si133a and si133b are specific and that $\Delta 133p53\alpha$ inhibits G1 arrest in U2OS-ctrl cells.

Regarding apoptosis (Figure 5F), in U2OS-ctrl cells transfected with si133a or si133b and compared with cells transfected with siNS, a statistically significant increase in the percentage of apoptotic cells was detected, suggesting that a low dose of doxorubicin can trigger apoptosis if cells are depleted of $\Delta 133p53\alpha$. Consistent with this, in U2OS- $\Delta 133p53$ cells transfected with si133a or si133b a statistically significant lower increase in the percentage of apoptotic cells was observed in response to treatment. This indicates that overexpression of $\Delta 133p53\alpha$ rescued the resistance to




Figure 5 $\Delta 133p53\alpha$ antagonizes DNA damage-induced apoptosis and G1 arrest without preventing p53-dependent G2 cell cycle arrest. U2OS-ctrl and U2OS- $\Delta 133p53$ cells were generated after stable transfection with the empty pcDNA3 or the pcDNA3- $\Delta 133p53$ expression vectors, respectively, as described in Material and Methods. Cells transfected for 24 h with 50 nM of si133a, si133b, siTA (siRNA specific for FLP53) or siNS (as indicated), were left untreated (-) or treated (+) for 1 h with 0.5 μ M of doxorubicin (Doxo), and incubated for a further 24 h before harvesting. Western blot analysis of U2OS- $\Delta 133p53$ cells (A) and U2OS-ctrl cells (B). p53 and its isoforms were revealed with the CM1 antibody. Tubulin was used as a protein loading control. C (a-f) Cell cycle analysis by flow cytometry after BrdU pulse labeling of U2OS-ctrl and U2OS- $\Delta 133p53$ cells treated as described above. These experiments were carried out in parallel with the western blot analyses described above and a representative BrdU pulse labeling experiment is shown (C). The average of the percentage of cells in G1 (D) and G2 (E) are shown. (F) Apoptosis assay. In parallel to the western blot analyses described above, cells were treated as described above and Annexin V-FITC flow cytometric analysis was carried out. The average of the percentage of apoptotic cells is shown. Student's *t*-test was performed and *P*-values are indicated (the student's *t*-tests were carried out by comparing percentages of U2OS-ctrl cells transfected with si133a, si133b or siTA, to percentages of U2OS-ctrl cells transfected with siNS, after doxorubicin treatment). All results shown are the average of at least three separate individual experiments

apoptosis in response to a low dose of doxorubicin confirming that endogenous $\Delta 133p53\alpha$ inhibits p53-mediated apoptosis in U2OS-ctrl cells.

Altogether, our results show that in response to a low dose of doxorubicin, endogenous $\Delta 133p53\alpha$ antagonizes p53-mediated apoptosis and G1 arrest, without inhibiting p53-dependent G2 arrest. This indicates that $\Delta 133p53\alpha$ does not exclusively inactivate p53. Moreover, it demonstrates that the cellular response to DNA damage could be regulated by modulating $\Delta 133p53\alpha$ expression.

Human $\Delta 133p53\alpha$ can form a protein complex with p53 and can differentially regulate *p21*, *HDM2* and *Bcl-2* expression in response to stress.

We have previously reported that ectopic $\Delta 133p53\alpha$ can act in a dominant-negative manner toward p53.⁷ To explain the regulation of p53 activities by $\Delta 133p53\alpha$, we investigated whether $\Delta 133p53\alpha$ could directly interact with p53. Co-immunoprecipitation assays were carried out on p53-null H1299 cells transfected with $\Delta 133p53\alpha$ and/or p53, using the mouse monoclonal antibody DO-1, recognizing FLp53 but not $\Delta 133p53\alpha$. Immunoprecipitated proteins were then analyzed by western blot with the rabbit polyclonal antibody (CM1), recognizing FLp53 and $\Delta 133p53\alpha$. The results clearly show that $\Delta 133p53\alpha$ can form a protein complex with p53 (Figure 6a).

We then studied whether endogenous $\Delta 133p53\alpha$ could regulate p53 target gene expression in response to DNA damage. In this study, we focused on a few p53 target genes (*p21*, *HDM2* and *Bcl-2*), implicated in cell cycle progression and apoptosis. *p21* encodes a cyclin-dependent kinase inhibitor involved in G1 and G2 cell cycle arrest,²⁰ whereas *HDM2* is an E3-ubiquitin ligase that regulates p53 protein degradation.^{21,22} Both *p21* and *HDM2* genes are directly

transactivated by p53 in response to stress, whereas *Bcl-2* is an anti-apoptotic gene repressed by p53.^{23,24}

Their expression was determined using western blot analysis (Figure 6b), using protein extracts from U2OS-ctrl cells analyzed in Figure 5B. RT-qPCR analysis was also performed in parallel (Supplementary Figure D). Doxorubicin treatment induced the expression of *p21* and *HDM2* at the mRNA and protein levels, but had no effect on *Bcl-2* expression (Supplementary Figure D and Figure 6b lane 2 compared with 1). Depletion of FLp53 by siTA after doxorubicin treatment strongly inhibited *p21* and *HDM2* at the mRNA and protein levels, without altering *Bcl-2* expression (Supplementary Figure D and Figure 6b lane 5 compared with 2). This confirms that in U2OS-ctrl cells, induction of *p21* and *HDM2* expression in response to a low dose of doxorubicin is p53-dependent, whereas it suggests that *Bcl-2* expression in U2OS-ctrl cells is not p53-dependent. Then, we compared with siNS, the effect of $\Delta 133p53\alpha$ depletion by si133a or si133b on the expression of *p21*, *HDM2* and *Bcl-2*, in cells treated with doxorubicin (Supplementary Figure D and Figure 6b lanes 3, 4 compared with 2). Depletion of $\Delta 133p53\alpha$ significantly increased the expression of *p21* mRNA, but did not alter *p21* protein expression. Interestingly, $\Delta 133p53\alpha$ depletion reduced the expression of *HDM2* and *Bcl-2* at both protein and mRNA levels. This suggests that $\Delta 133p53\alpha$ can increase *Bcl-2* expression and contributes to the induction of *HDM2* expression, in response to treatment. Therefore, our results show that $\Delta 133p53\alpha$ can differentially regulate *p21*, *HDM2* and *Bcl-2* expression and that $\Delta 133p53\alpha$ can directly interact with p53.

Altogether, we show that p53-mediated expression of $\Delta 133p53\alpha$ in response to a low dose of doxorubicin, leads to the inhibition of p53-mediated apoptosis and G1 cell cycle arrest, without inhibiting p53-mediated G2 cell cycle arrest. Moreover, we show that $\Delta 133p53\alpha$ can directly interact with




Figure 6 $\Delta 133p53\alpha$ directly interacts with p53 and differentially regulates *p21*, *HDM2* and *Bcl-2* expression. (a) Co-immunoprecipitation of $\Delta 133p53\alpha$ with p53. H1299 cells were transfected with pSV-p53 and/or pSV- $\Delta 133p53\alpha$ expression vectors, as indicated. Extracted proteins were immunoprecipitated with the mouse monoclonal antibody DO-1 or with a nonrelevant mouse monoclonal IgG antibody, as indicated. DO-1 is specific for FLp53 and does not bind $\Delta 133p53\alpha$. Protein content was then analyzed by western blot analysis using the rabbit polyclonal antibody (CM1), recognizing FLp53 and $\Delta 133p53\alpha$. 10% of the input was loaded as a control. (b) Western blot analysis of p53 target genes (*p21*, *HDM2* and *Bcl-2*). In parallel to the cell cycle analysis and apoptosis assay, protein extracts from U2OS-ctrl cells treated as described in Figure 5B, were analyzed by western blotting using the corresponding antibodies. Actin was used as a protein loading control

p53 and can differentially regulate the expression of *p21*, *HDM2* and *Bcl-2* in response to doxorubicin. This indicates that $\Delta 133p53\alpha$ does not exclusively inhibit p53, but rather modulates p53 activities. Of note, we cannot exclude that it can modulate gene expression independently of p53.

Discussion

We have recently reported that the human *p53* gene encodes nine different p53 isoforms, which can modulate p53 target gene expression, in a promoter-dependent manner.⁶ In this study, we investigated the regulation of *p53*'s internal promoter leading to $\Delta 133p53\alpha$ expression and the biological activities of endogenous $\Delta 133p53\alpha$ in response to a low dose of doxorubicin.

We determined that the initiation site of the *p53* internal promoter is located within the last 250 bp of intron-4 of the human *p53* gene. Moreover, we identified a functional p53RE composed of five putative decamers at the junction of exon-4 and intron-4. Further analysis will determine whether all five decamers can confer responsiveness to p53, p63 and/or p73. By bioinformatics analysis, we determined that the *p53* internal promoter could be responsive to cell proliferation signals (AP1, Elk1, N-myc and E2F), hypoxia (HIF-1 α), heat shock (HSF1) or hormones (estrogen receptor). In addition, we identified a silencer region (position 1042–1304) containing response elements to the repressor ZNF219 and CBF1.

To date, it is not possible to specifically quantify the expression of each separate $\Delta 133p53$ isoform ($\Delta 133p53\alpha$, $\Delta 133p53\beta$ and $\Delta 133p53\gamma$), encoded from the *p53* internal promoter. Hence, to quantify the mRNA level of the $\Delta 133p53$ isoforms, we designed primers and probe specific for the 5'UTR of $\Delta 133p53$ mRNAs, absent in FLp53 mRNA. We showed that the human *p53* internal promoter is induced in response to doxorubicin or Act D treatment in normal and in cancer cell lines expressing WTP53, suggesting that the p53-mediated regulation of its own internal promoter is conserved through evolution.²⁵

Consistently, the expression of $\Delta 133p53$ mRNAs is associated with an increase in $\Delta 133p53\alpha$ protein level only in normal cells and in cancer cell lines expressing WTP53 as determined by transfection of two distinct siRNAs (si133a and si133b), specific for the $\Delta 133p53$ mRNA variants. The endogenous $\Delta 133p53\alpha$ protein corresponds to a band at 35 kDa. It is noteworthy that ectopic and endogenous $\Delta 133p53\alpha$ give a band at 35 kDa and a weaker band at 32 kDa, in U2OS cells. We assume that the band at 32 kDa corresponds to a post-translationally modified form of $\Delta 133p53\alpha$.

We have recently published that $\Delta 113p53$, the zebrafish homolog of human $\Delta 133p53\alpha$, prevents p53-mediated apoptosis in response to embryonic defects or DNA damage²⁵ and that human $\Delta 133p53\alpha$ can inhibit replicative senescence.¹⁴ We investigated whether the cellular response to DNA damage could be regulated by modulating $\Delta 133p53\alpha$ expression. We determined that treatment of U2OS-ctrl cells with doxorubicin (0.5 μ M, 1 h) induces exclusively p53-dependent G2 cell cycle arrest without promoting G1 cell cycle arrest and p53-dependent apoptosis. Then, we established that depletion of $\Delta 133p53$ mRNAs by si133a or si133b changes

the cellular response of U2OS cells treated with doxorubicin (0.5 μ M, 1 h), increasing the proportion of cells undergoing apoptosis and G1 cell cycle arrest. Overexpression of $\Delta 133p53\alpha$ restores resistance to apoptosis and abolition of G1 cell cycle arrest without preventing p53-mediated G2 cell cycle arrest. The inhibition of p53-mediated apoptosis and G1 cell cycle arrest in response to $\Delta 133p53\alpha$ expression is consistent with our previous reports showing that $\Delta 133p53\alpha$ can function in a dominant-negative manner toward p53.^{6,7,14} The direct interaction of $\Delta 133p53\alpha$ with p53 is in support of this mechanism. However, as the overexpression of $\Delta 133p53\alpha$ did not inhibit p53-dependent G2 cell cycle arrest, it indicates that $\Delta 133p53\alpha$ does not exclusively act by inactivating p53. Indeed, $\Delta 133p53\alpha$ represses *p21*, whereas it induces *Bcl-2* and *HDM2* expression in response to doxorubicin, suggesting that many genes are differentially regulated by $\Delta 133p53\alpha$ to modulate cell fate outcome in response to DNA damage. Further experiments will determine whether it can regulate gene expression independently of p53. Our findings may have profound significance to extend our understanding of the mechanisms, by which p53 exerts its tumor suppressor activity. They demonstrate a new feedback loop, in which p53-induced $\Delta 133p53\alpha$ functions to modulate the cellular response to DNA damage.

Materials and Methods

p53 internal promoter constructs. The *p53* internal promoter, corresponding to the region 11 523–13 076 bp of the human *p53* gene (accession no. X54156, NCBI), was generated by PCR using the primers p53RE-a fwd and p53RE-a rev (Table 1). The PCR fragment was first cloned into the pCR4-TOPO vector using the TOPO TA Cloning kit (Invitrogen, Paisley, UK) and was further subcloned into the pGL3-basic plasmid, upstream of the luciferase reporter gene, to generate the pi3i4-luc construct (construct a in Figure 1A). Subsequently, a number of deletion constructs of pi3i4-luc (b, c, d and e in Figure 1A) were made by enzymatic digestion using various restriction enzymes, followed by religation and subcloning of the obtained fragments. Two other pi3i4-luc constructs (constructs c and d in Figure 2A), with or without p53REs, were generated by PCR using the primers' combination p53RE-b fwd/p53RE-a rev and p53RE-c fwd/p53RE-a rev for constructs b and c, respectively (Figure 2A and Table 1). Site-directed mutagenesis of the identified p53REs was carried out by PCR on the pi3i4-luc, using the primers Mut-p53RE fwd and Mut-p53RE rev (Table 1). All generated constructs were verified by DNA sequencing.

Dual luciferase assay. H1299 cells (3×10^4) were seeded in 24-well plates, 24 h before transfection. Two hours before transfection, media were replaced with 0.5 ml of fresh complete DMEM. Each transfection was performed in duplicate, and all results shown are the average of at least three separate individual experiments. For each well, 0.5 μ g of each p53 internal promoter construct (as indicated in the legends) and 50 ng of the Renilla luciferase reporter plasmid were co-transfected with 200 ng of the FLp53 expression vector or with the pSI (empty expression vector), used as negative control. The Renilla luciferase reporter plasmid was used as an internal control. Luciferase assays were performed as previously described.²⁶

Cell culture and generation of stable cell lines. The different human cell lines used in our study were: the non-small lung carcinoma cell line H1229 (p53-null), the osteosarcoma cell line U2OS (WTP53), the colon cell lines HCT116 (WTP53), the breast cancer cell line MCF7 (WTP53) and the primary NHDF. The MCF7 stable line overexpressing a dominant negative form of p53 (MCF7-DDp53)²⁷ was also used. The HCT116-/-, devoid of FLp53 expression, were kindly provided by Professor Vogelstein's lab (The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, MD, USA).¹⁷ Two U2OS stable cell lines were generated after transfection with either the empty pcDNA-3 expression vector (U2OS-ctrl) or with the pcDNA3- $\Delta 133p53$ expression vector (U2OS- $\Delta 133p53$). The heterogeneous populations of both cell lines were used in

Table 1 PCR primers used for cloning, ChIP and RT-qPCR assays

Primers for cloning and mutagenesis of p53 internal promoter
p53RE-a fwd: 5'-ACAGGAGGTGGGAGCAGGGCAGGTA-3'
p53RE-a rev: 5'-GTTGGCAAACATCTTGTGAGGGC-3'
p53RE-b fwd: 5'-AAAACCTACCAGGGCAGCTACGGT-3'
p53RE-c fwd: 5'-GGAACCTTTGGGATTCTCTTCACCTTA-3'
Mut-p53RE fwd: 5'-CTGGGACAGCAAATCTGTACAGTGCACG
GTCAG-3'
Mut-p53RE rev: 5'-CTGACCGTGCACGTGACAGATTTGCTGTC
CCAG-3'

Primers for ChIP assay on p53 internal promoter
ChIP-p53RE fwd: 5'-CAGGGCAGCTACGGTTTCC-3'
ChIP-p53RE rev: 5'-GCAACTGACCGTGCAAGTCA-3'
ChIP-p53RE probe: fam- 5'-TGCATTCTGGGACAGCCAAGTC-3'-
tamra
ChIP-Exon8 fwd: 5'-GAATCTCCGCAAGAAAGG-3'
ChIP-Exon8 rev: 5'-TTGCTTACCTCGCTTAGTG-3'
ChIP-Exon8 probe: fam- 5'-CTCACCACGAGCTGCCCCAG-3'-
tamra

Primers for RT-qPCR
mRNA-p53RE fwd: 5'-ACTCTGTCTCCTTCTCTTCTACAG-3'
mRNA-p53RE rev: 5'-GTGTGGAATCAACCCACAGCT-3'
mRNA-p53RE probe: fam- 5'-TCCCCTGCCCTCAACAAGATG
TTTTGCC-3'-tamra
mRNA-TBP fwd: 5'-CACGAACCACGGCACTGATT-3'
mRNA-TBP rev: 5'-TTTTCTTGCTGCCAGTCTGGAC-3'
mRNA-TBP probe: fam- 5'-TGTGCACAGGACCAAGAGTGAA
GA-3'-tamra

Abbreviations: ChIP, chromatin immunoprecipitation; p53RE, p53 responsive element

the experiments, no clones were isolated. NHDF cells were kindly provided by Dr C Pourreyron (University of Dundee, Ninewells Hospital, UK). H1299 cells were cultured in RPMI medium supplemented with 10% fetal calf serum and 100 μg/ml penicillin/streptomycin. All the other cell lines were cultured in DMEM medium supplemented with 10% fetal calf serum and 100 μg/ml penicillin/streptomycin.

RNA extraction, cDNA synthesis, RT-qPCR and ChIP assay. Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Crawley, UK) and treated with DNase (Qiagen) before reverse transcription, which was carried out using random hexamers (Promega, Southampton, UK) and Superscript II reverse transcriptase (Invitrogen). qPCR was performed on Stratagene MX3005P. p53 specific primers and probes were designed in our laboratory (Table 1) and purchased from MWG (Eberberg, Germany). RT-qPCR analyses for the *p21*, *Bax*, *HDM2* and *Bcl2* genes were performed as previously described.^{28,29} All measurements were normalized to the expression of the TATA box-binding protein (*TBP*) gene. p53 specific ChIP assay was conducted on MCF7 cells, as previously described using anti-p53 monoclonal antibody, DO-1.⁶

Western blot analysis. Cells lysates were separated by 4–12% SDS-PAGE (Novagen system, Birmingham, UK), transferred to a nitrocellulose membrane and blotted with various antibodies. The primary antibodies used were the following: anti-p53 CM1,³⁰ anti-HDM2 4B2,²⁸ p21 (Calbiochem, Nottingham, UK), PARP (Roche, Welwyn Garden City, UK), Bax, Bcl2 and actin (Santa Cruz, Heidelberg, Germany). All secondary horseradish peroxidase conjugated antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).

Immunoprecipitation assay. H1299 (10⁶ cells per 10-cm dish) were co-transfected with 2 μg pSV-p53 expression vector driven by the *SV40* promoter and/or 2 μg pSV-Δ133p53 expression vector driven by the *SV40* promoter. For each transfection mix, the concentration of the *SV40* promoter was balanced with the *SV40* empty expression vector. Fugene (Boehringer, Bracknell, UK) was used as a transfection reagent. Immunoprecipitation was carried out as previously described⁶ with anti-p53 mouse monoclonal antibody DO-1.

Protein content was then analyzed by western blot with anti-p53 rabbit polyclonal antibody (CM1), as previously described.⁶

siRNA transfection, apoptosis and cell cycle analyses. U2OS (10⁵ cells per 6-well plate) were transfected with the appropriate siRNA using oligofectamine (Invitrogen), treated with doxorubicin and further incubated for 24 h before harvesting for apoptosis and cell cycle assays. The efficiency of si133a, si133b and siTA was assessed by RT-qPCR (Supplementary Figures C1 and C2). Apoptotic cells were quantified using an Annexin V-fluorescein isothiocyanate kit (Biosciences, Cambridge, UK), according to the manufacturer's instructions and were analyzed by flow cytometry (Becton Dickinson, Oxford, UK). Cell cycle analysis was carried out using BrdU (Sigma, Bookham, UK) pulse labeling and flow cytometry, as previously described³¹ and according to the manufacturer's instructions.

Conflict of interest

The authors declare no competing financial interest.

Acknowledgements. Mustapha Aoubala is supported by Breast Cancer Campaign, Fiona Murray-Zmijewski was supported by Breast Cancer Campaign and MRC. Marie P Khoury and Stephane Perrier are supported by Inserm (Institut National de la Santé Et de la Recherche Médicale), Hugo Bernard is supported by Ligue Nationale Contre le Cancer. Kenneth Fernandes and Jean-Christophe Bourdon are supported by Cancer-Research, UK. We thank Drs Mark Saville and Alice Machado-Silva for their constructive discussions.

1. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. *Cell Death Differ* 2006; **13**: 1017–1026.
2. Braithwaite AW, Prives CL. p53: more research and more questions. *Cell Death Differ* 2006; **13**: 877–880.
3. Vousden KH, Lane DP. p53 in health and disease. *Nat Rev Mol Cell Biol* 2007; **8**: 275–283.
4. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. *Cell Death Differ* 2006; **13**: 941–950.
5. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. *Cell Death Differ* 2006; **13**: 951–961.
6. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP *et al*. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 2005; **19**: 2122–2137.
7. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. *Cell Death Differ* 2006; **13**: 962–972.
8. Boldrup L, Bourdon JC, Coates PJ, Sjöstrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. *Eur J Cancer* 2007; **43**: 617–623.
9. Ebrahimji M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K. Expression of novel p53 isoforms in oral lichen planus. *Oral Oncol* 2008; **44**: 156–161.
10. Bourdon JC. p53 and its isoforms in cancer. *Br J Cancer* 2007; **97**: 277–282.
11. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruslerud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. *Clin Cancer Res* 2006; **12**: 3985–3992.
12. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Wojtesek B, Lane DP *et al*. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res* 2008; **14**: 1659–1668.
13. Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R *et al*. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. *Eur J Cancer* 2008; **44**: 131–141.
14. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ *et al*. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. *Nat Cell Biol* 2009; **11**: 1135–1142.
15. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. *Mol Cancer Res* 2004; **2**: 371–386.
16. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Deubire B *et al*. Further characterisation of the p53 responsive element – identification of new candidate genes for trans-activation by p53. *Oncogene* 1997; **14**: 85–94.
17. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP *et al*. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 1998; **282**: 1497–1501.
18. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U *et al*. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. *Oncogene* 2002; **21**: 6722–6728.
19. Allan LA, Fried M. p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. *Oncogene* 1999; **18**: 5403–5412.
20. Medema RH, Klompaker R, Smits VA, Rijkse G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. *Oncogene* 1998; **16**: 431–441.
21. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. *Oncogene* 1993; **8**: 3411–3416.

22. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. *Genes Dev* 1994; **8**: 1739–1749.
23. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. *Cancer Res* 1994; **54**: 3131–3135.
24. Bredow S, Juri DE, Cardon K, Tesfaigzi Y. Identification of a novel Bcl-2 promoter region that counteracts in a p53-dependent manner the inhibitory P2 region. *Gene* 2007; **404**: 110–116.
25. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP *et al*. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. *Genes Dev* 2009; **23**: 278–290.
26. Bourdon JC, Renzing J, Robertson PL, Fernandes KN, Lane DP. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. *J Cell Biol* 2002; **158**: 235–246.
27. Shaulian E, Haviv I, Shaul Y, Oren M. Transcriptional repression by the C-terminal domain of p53. *Oncogene* 1995; **10**: 671–680.
28. Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC *et al*. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C *in vivo*. *J Biol Chem* 2004; **279**: 42169–42181.
29. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. *EMBO J* 2007; **26**: 976–986.
30. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in *Escherichia coli*. *J Cell Sci* 1992; **101** (Pt 1): 183–189.
31. Hoy CA, Carswell C, Schimke RT. Bromodeoxyuridine/DNA analysis of replication in CHO cells after exposure to UV light. *Mutat Res* 1993; **290**: 217–230.

Supplementary Information accompanies the paper on Cell Death and Differentiation website (<http://www.nature.com/cdd>)